Literature DB >> 3732052

Potential of continuous tumour cell lines for establishing patterns of cross-resistance and collateral sensitivity in vitro.

B T Hill.   

Abstract

The potential value of continuous tumour cell lines for establishing in vitro patterns of cross-resistance and collateral sensitivity has been examined. Results are presented for a series of sublines of the murine L5178Y lymphoma in which resistance has been induced in vitro by repeated exposure to the following antitumour drugs: methotrexate, 5-fluorouracil, adriamycin, vincristine and vindesine. A comparison has also been made between data derived from a murine (L5178Y) and a human tumour (LoVo) cell line, derived from a colon carcinoma, in which 5-fluorouracil resistance has been induced. Preliminary results suggest that the human tumour model may be more relevant clinically. It has also been demonstrated that prior exposure to fractionated X-irradiation in vitro can result in the expression of resistance or collateral sensitivity, depending on the drug evaluated. Furthermore, the expression of cross-resistance to certain drugs appears to differ, depending on the method used to induce or select for resistance in vitro. If confirmed, these latter observations may have major clinical implications for the combined modality approach to cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732052

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  4 in total

1.  High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk.

Authors:  H Wilke; P Preusser; U Fink; W Achterrath; L Lenaz; M Stahl; C Schober; H Link; H J Meyer; B Lucke
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

2.  Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer.

Authors:  Catherine Gutierrez; Caroline K Vilas; Catherine J Wu; Aziz M Al'Khafaji
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

Review 3.  From Chemotherapy to Combined Targeted Therapeutics: In Vitro and in Vivo Models to Decipher Intra-tumor Heterogeneity.

Authors:  Guido Gambara; Manuela Gaebler; Ulrich Keilholz; Christian R A Regenbrecht; Alessandra Silvestri
Journal:  Front Pharmacol       Date:  2018-02-14       Impact factor: 5.810

Review 4.  New insights from the widening homogeneity perspective to target intratumor heterogeneity.

Authors:  Mengying Tong; Ziqian Deng; Xiaolong Zhang; Bin He; Mengying Yang; Wei Cheng; Quentin Liu
Journal:  Cancer Commun (Lond)       Date:  2018-05-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.